AQR Arbitrage’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

AQR Arbitrage’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-71,760	Closed	-$712K	–	1257
2021 Q3	$712K	Buy	71,760 +54,260	+310%	+$539K	0.02%	548
2021 Q2	$174K	Hold	17,500	–	–	﹤0.01%	786
2021 Q1	$174K	Sell	17,500 -7,500	-30%	-$79.9K	0.01%	783
2020 Q4	$270K	Hold	25,000	–	–	0.01%	866
2020 Q3	$259K	Hold	25,000	–	–	0.01%	475
2020 Q2	$250K	Buy	+25,000	New	+$249K	0.01%	427

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

AQR Arbitrage's STLN Position: Q4 2021 in Review

AQR Arbitrage sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 71,760 shares — an estimated $712K sold.

AQR Arbitrage first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $712K in Q3 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

AQR Arbitrage reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
AQR Arbitrage sold 71,760 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $712K.
AQR Arbitrage first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
AQR Arbitrage's Starling Oncology Institute, Inc. Common Stock position peaked at $712K in Q3 2021.
21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on AQR Arbitrage's 13F filing for Q4 2021, filed 14 Feb 2022.